Top Story

BLOG: The big and small picture with MP3 and Cyclo G6

March 16, 2018

EyeGate reports 2017 net loss of $13.2 million

March 16, 2018
EyeGate Pharmaceuticals reported a net loss of $13.2 million in 2017 compared with a net loss of $13.3 million the previous year, according to a press release. Research…

Nicox, Bausch + Lomb restructure Vyzulta financial terms

March 16, 2018
Nicox and Bausch + Lomb have agreed to new financial terms for Vyzulta, which includes an additional $20 million in potential milestone payments, according to a press…

Rocket Pharmaceuticals posts $19.6 million annual net loss

March 16, 2018
Rocket Pharmaceuticals, which recently merged with Inotek Pharmaceuticals, reported a net loss of $19.6 million, or $219.49 per share, in 2017 compared with a net loss…
Meeting News

No difference in pain reported with smaller-gauge intravitreal injection needle

March 15, 2018
PHILADELPHIA — Patients who received intravitreal injections experienced no less pain with a slightly smaller diameter needle, according to a study presented by…
More Headlines »
Original Article

Nepafenac Ophthalmic Suspension 0.3% for the Management of Ocular Pain After Photorefractive Keratectomy

Journal of Refractive Surgery, March 2018, Volume 34 Issue 3
To investigate the effect of nepafenac 0.3% in a once daily dosage regarding pain and healing after photorefractive…
More »

Case Presentation: CyPass Stent in the Left Eye and an iStent in the Right Eye

This activity is supported by educational grants from Aerie Pharmaceuticals, Inc.; Alcon Laboratories, Inc.; Bausch + Lomb; Glaukos Corporation; and Novartis Pharmaceuticals Corporation.

In this CME activity, the clinical course of a patient with a CyPass Stent in the left eye and an iStent in the right
More »
Resource Centers
Video From OSN Europe
Meeting News

VIDEO: Role of posterior capsule malformation explored

February 22, 2018
More »